Mesenchymal Stromal Cells: Current Understanding and Clinical Status

被引:749
作者
Salem, Husein K. [1 ]
Thiemermann, Chris [1 ]
机构
[1] Queen Mary Univ London, Ctr Translat Med & Therapeut, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, London EC1M 6BQ, England
关键词
Stem cells; Mesenchymal stromal cells; T lymphocytes; Dentritic cells; Myocardium; Kidney; HUMAN BONE-MARROW; ACUTE MYOCARDIAL-INFARCTION; ACUTE-RENAL-FAILURE; LEFT-VENTRICULAR FUNCTION; HEMATOPOIETIC STEM-CELLS; ANTIGEN-PRESENTING CELL; NATURAL-KILLER-CELLS; IN-VITRO; T-CELL; CHEMOKINE RECEPTORS;
D O I
10.1002/stem.269
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Multipotent mesenchymal stromal cells (MSCs) represent a rare heterogeneous subset of pluripotent stromal cells that can be isolated from many different adult tissues that exhibit the potential to give rise to cells of diverse lineages. Numerous studies have reported beneficial effects of MSCs in tissue repair and regeneration. After culture expansion and in vivo administration, MSCs home to and engraft to injured tissues and modulate the inflammatory response through synergistic downregulation of proinflammatory cytokines and upregulation of both prosurvival and antiinflammatory factors. In addition, MSCs possess remarkable immunosuppressive properties, suppressing T-cell, NK cell functions, and also modulating dentritic cell activities. Tremendous progress has been made in preclinical studies using MSCs, including the ability to use allogeneic cells, which has driven the application of MSCs toward the clinical setting. This review highlights our current understanding into the biology of MSCs with particular emphasis on the cardiovascular and renal applications, and provides a brief update on the clinical status of MSC-based therapy. STEM CELLS 2010; 28: 585-596
引用
收藏
页码:585 / 596
页数:12
相关论文
共 129 条
[21]   Programmed myocyte cell death affects the viable myocardium after infarction in rats [J].
Cheng, W ;
Kajstura, J ;
Nitahara, JA ;
Li, BS ;
Reiss, K ;
Liu, Y ;
Clark, WA ;
Krajewski, S ;
Reed, JC ;
Olivetti, G ;
Anversa, P .
EXPERIMENTAL CELL RESEARCH, 1996, 226 (02) :316-327
[22]  
Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.0.CO
[23]  
2-C
[24]   Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-β, and Copaxone [J].
Croitoru-Lamoury, Juliana ;
Lamoury, Francois M. J. ;
Zaunders, John J. ;
Veas, Laura A. ;
Brew, Bruce J. .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2007, 27 (01) :53-64
[25]   Donor-Derived Mesenchymal Stem Cells Suppress Alloreactivity of Kidney Transplant Patients [J].
Crop, Meindert J. ;
Baan, Carla C. ;
Korevaar, Sander S. ;
IJzermans, Jan N. M. ;
Alwayn, Ian P. J. ;
Weimar, Willem ;
Hoogduijn, Martin J. .
TRANSPLANTATION, 2009, 87 (06) :896-906
[26]   Mesenchymal stem cells reside in virtually all post-natal organs and tissues [J].
da Silva Meirelles, Lindolfo ;
Chagastelles, Pedro Cesar ;
Nardi, Nance Beyer .
JOURNAL OF CELL SCIENCE, 2006, 119 (11) :2204-2213
[27]   Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium - Short- and long-term effects [J].
Dai, WD ;
Hale, SL ;
Martin, BJ ;
Kuang, JQ ;
Dow, JS ;
Wold, LE ;
Kloner, RA .
CIRCULATION, 2005, 112 (02) :214-223
[28]   Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3 [J].
De Becker, Ann ;
Van Hummelen, Paul ;
Bakkus, Marleen ;
Vande Broek, Isabelle ;
De Wever, Joke ;
De Waele, Marc ;
Van Riet, Ivan .
HAEMATOLOGICA, 2007, 92 (04) :440-449
[29]   Mesenchymal stem cells: Biology and potential clinical uses [J].
Deans, RJ ;
Moseley, AB .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (08) :875-884
[30]   Update on mechanisms of ischemic acute kidney injury [J].
Devarajan, Prasad .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (06) :1503-1520